Prevalence of Type 2 and Type 1 Diabetes in Psoriatic Arthritis: An Italian Study. Issue 2 (11th March 2022)

• Record Type: Journal Article
• Authors: Ciaffi, Jacopo; Mele, Giulio; Mancarella, Luana; Brusi, Veronica; Lisi, Lucia; Faranda Cordella, Jacopo; Lubrano, Ennio; D'Angelo, Salvatore; Meliconi, Riccardo; Ursini, Francesco
• Is Part Of: Journal of clinical rheumatology. Volume 28:Issue 2(2022)
• Page Start: e324
• Page End: e329
• Publication Date: 2022-03-11
• Subjects: arthritis -- psoriatic -- diabetes mellitus type 2 -- diabetes mellitus type 1; Rheumatism -- Periodicals; Rheumatology -- Periodicals; Musculoskeletal system -- Diseases -- Periodicals; Musculoskeletal Diseases -- Periodicals; Rheumatic Diseases -- Periodicals; Rhumatisme -- Périodiques; Rhumatologie -- Périodiques; Appareil locomoteur -- Maladies -- Périodiques; Musculoskeletal system -- Diseases; Rheumatism; Rheumatology; Periodicals; 616.723005
• DOI: 10.1097/RHU.0000000000001706
• Languages: English
• ISSNs: 1076-1608

Abstract

Abstract : Objective: Psoriatic arthritis (PsA) is burdened by an increased susceptibility to cardiovascular diseases. Comorbid diabetes may represent one of the key factors contributing to this risk. The aim of our medical records review study was to investigate the prevalence of type 2 diabetes (T2D) and type 1 diabetes (T1D) in an Italian PsA cohort. Methods: The clinical records of all patients consecutively seen at our clinic with a diagnosis of PsA during a 12-month period were reviewed to identify comorbid T2D or T1D. For comparison, a 1:1 age- and sex-matched group of individuals with noninflammatory diseases was recruited. Results: The final study cohort comprised 408 patients. The prevalence of T2D was 7.8% (95% confidence interval, 5.6–10.8) in PsA and 4.4% in controls (95% confidence interval, 2.8–6.9; p = 0.04). Two cases (0.49%) of T1D were identified in the PsA cohort, whereas no cases were observed in controls. In a multivariate logistic regression model including age, disease duration, and body mass index (BMI) as covariates, increasing age (odds ratio [OR], 1.079; p = 0.006) and BMI (OR, 1.188; p = 0.011) but not PsA duration predicted being classified as having T2D. In a similar model accounting for age and BMI, average disease activity score including 28 joints and C-reactive protein showed a trend toward significance (OR, 1.639; p = 0.066). Conclusions: In conclusion, our data provide further support to the emerging evidence of an increased risk of T2D in PsA patients. Cardiometabolic comorbidity represents a significant aspect of integrated arthritis management to improve long-term cardiovascular outcomes and to provide a comprehensive treatment.